Kumar M Ashwini, Radhika Besta, Gollamudi Nishanth, Reddy Satya Prakash, Yaga Uday Shankar
Professor and HOD, Department of Oral Medicine and Radiology, MNR Dental College and Hospital , Telangana, India .
Senior Lecturer, Department of Oral Medicine and Radiology, MNR Dental College and Hospital , Telangana, India .
J Clin Diagn Res. 2015 May;9(5):ZE01-4. doi: 10.7860/JCDR/2015/11500.5905. Epub 2015 May 1.
Oral submucous fibrosis (OSMF) is a chronic, debilitating disease characterized by juxta epithelial fibrosis of the oral cavity and regarded as a potentially malignant disorder. Numerous treatment modalities ranging from various drugs to behavioral therapy have been tried with inconsistent results with varying degrees of success reflecting low predictability, requiring further evaluation and standardization. Novel treatment modality such as Hyperbaric oxygen therapy (HBOT) involves inhalation of 100% oxygen at increased atmospheric pressure usually ranging between 2.0 and 2.5 atmospheres for periods between 60 and 120 min. HBOT which can increase oxygen tension and delivery to oxygen-deficient tissue, is a supplementary therapy to improve hypoxic environment of OSMF and also possesses potent anti-inflammatory properties. This article enlightens on possible beneficial effects of HBOT in the management of OSMF at cellular and molecular level.
口腔黏膜下纤维化(OSMF)是一种慢性、使人衰弱的疾病,其特征为口腔上皮下纤维化,被视为一种潜在的恶性疾病。从各种药物到行为疗法等众多治疗方式都已尝试过,但结果不一,不同程度的成功反映出预测性较低,需要进一步评估和标准化。诸如高压氧治疗(HBOT)等新型治疗方式涉及在通常介于2.0至2.5个大气压的增高气压下吸入100%的氧气,持续时间为60至120分钟。HBOT可增加氧张力并向缺氧组织输送氧气,是一种改善OSMF缺氧环境的辅助疗法,还具有强大的抗炎特性。本文阐述了HBOT在细胞和分子水平上对OSMF治疗可能产生的有益作用。